Organ transplant recipients (OTR) are at increased risk of cutaneous squamous cell carcinoma, which may be related to reactivation of human papillomavirus (HPV) infections. Measurement of change in HPV antibodies after transplantation would help to explore this hypothesis. We measured antibodies to 34 HPV types on up to six occasions over 18 months in 441 OTRs from five European countries. At baseline (mean 24 days after transplantation), 80% of all OTRs were seropositive to at least one HPV type. The beta HPV genus had the highest seroprevalence (45%). For most HPV genera baseline seroprevalence peaked between 40 and 59 years old. Most OTRs retained their serostatus over time and antibody levels were stable. Seroprevalence in immunosuppressed OTRs is stable in the 18 months immediately after transplantation. Thus there is no short-term evidence that immunosuppression leads to new or reactivated skin infection with HPV sufficient to induce antibodies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.virol.2012.10.037DOI Listing

Publication Analysis

Top Keywords

human papillomavirus
8
organ transplant
8
transplant recipients
8
hpv
7
longitudinal study
4
seroprevalence
4
study seroprevalence
4
seroprevalence serostability
4
serostability human
4
papillomavirus types
4

Similar Publications

This systematic review and meta-analysis evaluate human papillomavirus (HPV) prevalence, genotype distribution, and associations with cervicovaginal microbiota and cytokine profiles among South African women, where cervical cancer ranks as the second most common cancer. PubMed, SCOPUS, and Web of Science were searched for studies on HPV infection up to 21 September 2024. The pooled prevalence was estimated using a random-effects model, with subgroup analyses by province, sample type, and HIV status.

View Article and Find Full Text PDF

Human Papillomavirus (HPV) infection is a significant global health concern linked to various cancers, particularly cervical cancer. Timely and accurate detection of HPV is crucial for effective management and prevention strategies. Traditional laboratory-based HPV testing methods often suffer from limitations such as long turnaround times, restricted accessibility, and the need for trained personnel, especially in resource-limited settings.

View Article and Find Full Text PDF

Background: Persistent inequities in access to vaccinations pose challenges for immunization programs worldwide. Innovations facilitating vaccine delivery, such as leveraging vaccine thermostability through a Controlled Temperature Chain (CTC), have emerged as a potential solution to increase coverage in low- and middle-income countries (LMICs) countries such as Côte d'Ivoire, reducing dependence on the cold chain and improving vaccine delivery efficiency. However, the added value of thermostable vaccines and their integration into national immunization programs is under-recognized by stakeholders.

View Article and Find Full Text PDF

Human papillomavirus (HPV) remains the most prevalent sexually transmitted infection in the United States (U.S.).

View Article and Find Full Text PDF

HPV Vaccines Among University Students: Understanding Barriers and Facilitators of Vaccine Uptake.

Vaccines (Basel)

December 2024

Department of Family, Population, and Preventative Medicine, Stony Brook Medicine, Stony Brook, NY 11794, USA.

Human papillomavirus (HPV) is the most common sexually transmitted infection and plays a significant role in cervical, penile, anal, vaginal, vulvar, and oropharyngeal cancers as well as non-cancerous genital warts and genital dysplasia. In the United States, there are approximately 46,000 new HPV-related cancers a year. There is an effective vaccine to prevent over 90% of these cancers and other HPV-related diseases; however, those that are aged 18-26 have the lowest vaccine rates among eligible age groups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!